NeoCart Tissue Implant Superior to Microfracture (Biloine Young @ OTW)
The regenerative medicine company Histogenics Corporation received encouraging news in an article in the Journal of Bone and Joint Surgery reporting the two-year results of a Phase 2 clinical trial of its product NeoCart Autologous Cartilage Tissue Implant (ACTI). The implant is designed for patients with grade II chondral injury to the femur (the cartilage in the knee).
NeoCart is an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the repair of full thickness cartilage lesions. The current standard of care for this problem is microfracture surgery which works by creating tiny fractures in the underlying bone. While this treatment is widely recommended as a primary treatment for chondral injury to the femur, outcome measures have been reported to plateau between 12 to 24 months.
The results of the two-year Histogenics study, as reported in the June 6 news release, are that NeoCart has a comparable safety profile to microfracture surgery, significantly improves pain and function within six months of treatment, provides significantly greater improvements in a greater ...
